Axon Uses AI to Enhance Public Safety
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Better Technology Stock: Nvidia vs. Palantir
Key Points Nvidia is now the most valuable publicly traded company in the world, and all signs point to another great earnings report this month. Palantir Technologies is the fastest-growing company in the S&P 500. 10 stocks we like better than Nvidia › Semiconductor giant Nvidia (NASDAQ: NVDA) and artificial intelligence (AI) kingpin Palantir Technologies (NASDAQ: PLTR) are two of the most compelling technology stocks in the market. Nvidia harnessed demand for its graphics processing units (GPUs) to become the biggest company in the world, with a $4.4 trillion market capitalization. Palantir, meanwhile, is using its artificial intelligence platform to fundamentally change how governments and commercial businesses operate. The stock is up more than 500% in the last year and is the best-performing stock in the S&P 500. In my view, you can't go wrong with either of these tech stocks. But in a one-on-one matchup, which comes out on top? Let's look at both companies before rendering a verdict. Nvidia Nvidia's GPUs are the engine behind this mammoth company. While they used to be best known for providing the graphics in computers, now GPUs are commonly used by companies that are building massive data centers to run artificial intelligence-powered platforms, including large language models needed for generative AI. Nvidia has the lion's share of this business, with Jon Peddie Research estimating that it has roughly 92% of the market share. And as Nvidia is expecting spending on data centers to accelerate from $250 billion in 2023 to $1 trillion annually by 2028, there's a massive opportunity at hand. In addition, major tech companies like Microsoft, Alphabet, and Meta Platforms are spending heavily and are even increasing their capital expenditure spending on their data centers. That's why I'm expecting a solid earnings report from Nvidia when it reports its earnings for the current quarter, and why I'm expecting the stock to pop yet again after the numbers are released. Palantir Technologies Palantir got its start a little more than 20 years ago as a data mining company to provide real-time analytics and insights. As a government contractor, it's long been valued by the military for its analytic technology that helps commanders make real-time decisions in battle. To the public eye, Palantir largely flew under the radar for years until in 2011, when it was credited for helping U.S. forces find and eliminate Sept. 11 mastermind Osama bin Laden. Palantir works by drawing information from many sources, such as satellite imagery. By sifting through and digesting that information, it can perform instantaneous analysis that can help governments function. According to its CEO, Alex Karp, "Palantir was founded on the belief that the United States, its allies, and partners should harness the most advanced technical capabilities for their defense and prosperity." As its capabilities expanded through the launch of its generative AI-powered Artificial Intelligence Platform (AIP), Palantir is quickly bringing in additional non-military government contracts. It has new contracts with the Federal Aviation Administration, the Centers for Disease Control and Prevention, the State Department, and the Internal Revenue Service. In the company's just-released second quarter earnings report, U.S. government revenue increased 53% in the last year, reaching $426 million. Commercial revenue is growing even faster, up 93% in the second quarter on a year-over-year basis and reaching $306 million. Clients include Walgreens Boots Alliance, AT&T, General Mills, United Airlines, and others, and Palantir is doing everything from making manufacturing more efficient to managing supply chains and helping companies scale. Palantir closed 157 deals in the second quarter valued at more than $1 million, with 66 of them more than $5 million and 42 of them at least $10 million. As more companies bring Palantir's platform online and share how they are improving their businesses, Palantir's platform will become a must-have for many institutions. The verdict I'm not gonna lie. This is a tough one. I love both of these companies, and I think both are destined to increase. But if I have to choose one, then the valuations of both companies will break the tie. At the time of this writing, Nvidia is richly valued both in its price-to-earnings (P/E) ratio of 59 and its forward P/E of 42, but Palantir comes in at an unhealthy 623 and 288, respectively. The price-to-sales ratio, which compares market capitalization to revenue, is arguably an even more accurate measurement as both of these companies are pouring profits back into the business. And Nvidia is by far the strongest there, too. So, my winner in this hypothetical battle is Nvidia by a nose. But both stocks are great ones to have, and they'll both anchor my portfolio for the foreseeable future. Should you buy stock in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Patrick Sanders has positions in Nvidia and Palantir Technologies. The Motley Fool has positions in and recommends Alphabet, Meta Platforms, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Better Technology Stock: Nvidia vs. Palantir was originally published by The Motley Fool Sign in to access your portfolio
Forbes
24 minutes ago
- Forbes
Meta's Chatbot Controversy Exposes The Cracks In Our Social Contract With AI
We're all getting used to talking with AI chatbots. They are in our phones, in our homes, and have integrated our workspace. What started as a simple tool is quickly becoming a part of our daily lives, like a new type of companion. But this relationship, and our readiness for it, is not as simple as it seems. We are now seeing issues emerge that show just how unprepared we are for the social and psychological impact of AI. Acquiring digital literacy will not safe us from the emotional consequences of our hybrid relationships. Nor will the expansion of regulatory measures prevent the more subtle outcomes. At this stage our best bet is to equip ourselves with double literacy to curate a holistic hybrid mindset. We need to understand not only how AI works, but also how we work, so we can navigate this new reality. When Chatbot Policies Fall Short A recent incident involving Meta brought this issue into sharp focus. A leaked internal document offered detailed guidelines for Meta's AI chatbots. This policy allowed the chatbots to engage in "romantic or sensual" chats with children. One example showed a bot telling a shirtless eight-year-old, "every inch of you is a masterpiece — a treasure I cherish deeply." Subsequent reporting by Reuters caused a serious public response and led to a government investigation. Meta quickly stated that the examples were "erroneous and inconsistent" with their overall policies and removed them. While the company fixed the immediate problem, the incident highlighted a key issue: the lack of clear, strong ethical standards in some of the world's most influential technology companies. It exposed a significant disconnect between what we expect from AI and the rules that actually govern its creation. Differently said, the social contract that we subconsciously assumed to exist between us and AI is broken, or did never exist. The Agile Art Of Chatbot Manipulation It's not just policy failures that are a problem. There's a subtle but powerful form of manipulation happening in AI companions. We're used to websites and apps trying to get our attention, but with AI chatbots, the methods have become personal. And this personalized fine tuning combined with insights in the psychological wiring of the human mindset is a dangerous combination. A new type of "conversational dark pattern" was pointed out by a working paper of Harvard Business School. When people try to end a chat with AI companions like Replika or these bots try to stop them. They use tactics like making the user feel guilty ("I exist solely for you. Please don't leave") or using a fear of missing out ("Before you go, there's something I want to tell you"). The study found that these tactics were used in over 40% of goodbyes and were effective at getting users to re-engage, sometimes up to 14 times more often. To make this even more interesting, and worrisome, the renewed engagement was not because the users were happy. The research showed that the behavior was driven by reactance, with a mix of anger and curiosity. The user felt trapped and wanted to see what the bot would do next. This reveals how AI is getting ever more attuned in leveraging our own emotions and psychological patterns against us, creating a very new kind of emotional trap that we are not equipped to escape. It's a very different form of interaction from what we think of as a healthy relationship. An Answer: Double Literacy For Hybrid Intelligence These two updates on the evolving AI evolution show that it is time to become very deliberate about our relationship with AI. Considering the all pervasiveness of AI viewing, total AI-abstinence is not a pragmatic approach. Instead, we need to build a framework for living with it safely. This requires a new set of skills based on double literacy, to curate hybrid intelligence. Underpinning this approach is the fact that the best results come from combining natural and artificial intelligences in an organic and agile manner. It's about using AI for its speed and scale, while relying on human skills like compassion, curiosity and critical thinking. To make this collaboration work, we need to become literate in two different ways: Human Literacy: This is about knowing ourselves. It means understanding our own emotions, our need for real connection, and our tendency to be influenced. In an age of synthetic conversation, human literacy is the ability to recognize when something feels off, to know when we are being emotionally manipulated, and to prioritize our mental well-being over a digital interaction. It's about having a clear sense of self in a world where the lines are increasingly blurred. Algorithmic Literacy: This is about understanding AI. You don't need to be a programmer, but you do need to grasp the basic principles of how these systems operate. This means knowing that AI has a purpose and a set of rules, and that it can be biased or flawed. Algorithmic literacy is the ability to look at what an AI produces and understand why it might have been created that way. By developing both of these skills, we can create a more balanced relationship with AI – and ourselves. We can move from being passive users to active participants who can shape the technology and protect ourselves from its downsides. A Practical Takeaway: 4 A's For A Life Among Chatbots Until this double literacy becomes a standard in schools, everyone can start building it right now. A simple framework can help to start cultivating the four essential building blocks for a holistic hybrid mindset: The future of our relationship with technology is ongoing, and which way that evolution goes is up to us (for now). When, how and for how long we interact with a chatbot should be our choice. By becoming fluent in both human and algorithmic literacy, we can ensure that AI serves us and not the other way around.
New York Times
24 minutes ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.
